Aquestive Therapeutics AQST 深 沪
等待开盘 03-26 09:30:00 美东时间
4.145
+0.265
+6.83%
华盛通- 最 高4.185
- 今 开3.91
- 成交量 118.60万股
- 最 低 3.91
- 昨 收 3.88
- 总市值 5.06亿
- 52周最高 7.55
- 市盈率 静 --
- 换手率 0.97%
- 52周最低 2.12
- 委 比 5.50%
- 总股本 1.22亿
- 历史最高 20.696
- 量 比 0.80
- 振 幅 7.09%
- 历史最低 0.618
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aquestive Therapeutics Announces Key Legal Leadership Transition
Aquestive Therapeutics ( ($AQST) ) just unveiled an announcement. On March 16, ...
03-20 19:57
Aquestive Therapeutics names Thomas A. Zalewski chief legal and compliance officer
Aquestive Therapeutics names Thomas A. Zalewski chief legal and compliance officer Thomas Zalewski was appointed chief legal officer and chief compliance officer at Aquestive, effective April 2, 2026. Zalewski was most recently a partner and chair of the Healthcare and Life Sciences practice at Day
03-20 19:03
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
Aquestive Therapeutics appoints Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, succeeding Lori J. Braender, who will continue as Corporate Secretary. Zalewski, with extensive experience in life sciences law, will support the company's mission to advance Anaphylm, the first oral epinephrine rescue medication. Braender, after nearly eight years in her roles, will focus on corporate governance. The c...
03-20 11:00
Aquestive Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer Matthew J. Greenhawt
Aquestive Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer Matthew J. Greenhawt Aquestive Therapeutics Inc. filed an initial statement of beneficial ownership for Matthew J. Greenhawt, Chief Medical Officer. The full filing can be accessed through the link below. D
03-11 21:20
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
Aquestive Therapeutics announced an inducement grant for CMO Matthew Greenhawt under its 2022 Equity Inducement Plan. The grant includes 75,000 RSUs and 50,000 non-qualified stock options, each vesting 25% after the first and second anniversaries, and 50% on the third. The options have a 10-year term and an exercise price based on March 9, 2026 closing price. The awards were approved by the independent Compensation Committee. Aquestive specialize...
03-09 20:01
AI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability
Aquestive Therapeutics, Inc. (AQST) has disclosed a new risk, in the Innovation...
03-06 14:01
Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook
The latest announcement is out from Aquestive Therapeutics ( ($AQST) ). On Marc...
03-05 05:37
Aquestive Therapeutics Q4 Earnings Assessment
Aquestive Therapeutics (NASDAQ:AQST) announced its Q4 earnings on Wednesday, Ma...
03-05 05:08
Aquestive Therapeutics Sees FY2026 Sales $46.000M-$50.000M vs $49.888M Est
Aquestive Therapeutics (NASDAQ:AQST) sees FY2026 sales of $46.000 million-$50.000 million vs $49.888 million analyst estimate.
03-05 05:03
Aquestive Therapeutics Q4 Adj. EPS $(0.15) Misses $(0.13) Estimate, Sales $13.015M Miss $13.284M Estimate
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 12.78 percent. This is a 21.05 percent increase over losses of $(0.19) per
03-05 05:02
